Digital biomarker startup Koneksa has raised $45 million in their Series C funding round. The round was led by AyurMaya, Takeda Ventures, Velocity Capital, McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital) Spring Mountain Capital and Waterline Ventures. 

The company plans to use the new cash to grow its digital-biomarker platform and the self-service tools in its clinical-data-integration products. It also plans to build out its science team, including adding Wagner as its first chief medical officer. 

Koneksa Health is a health data analytics startup created by Chris Benko in 2013. The startup helps researchers use bio-sensors, activity trackers and other technologies in their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets.

The startup also has a remote monitoring solution that includes a real-time patient alert and notification system. With COVID-19, the rise of remote monitoring, and virtual clinical trials created the circumstances for the rapid adoption and success of digital biomarkers. Koneksa will receive competition from Sonde and Apple and Biogen.

Koneksa has so far raised $70.6 million in their 4 funding rounds. In 2016, Takeda announced a collaboration with Koneska Health focused on using the startup's biosensor tools in the former's clinical trials.